Wang Zhiyu, Chen Zijin, Ma Xiaobo, Yu Haijin, Chen Xiaonong
Division of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hemodial Int. 2020 Apr;24(2):212-220. doi: 10.1111/hdi.12825. Epub 2020 Feb 11.
Heterotopic vascular calcification is a common complication of maintenance hemodialysis (MHD) patients. Galectin 3 (Gal-3) has been reported to be associated with cardiovascular calcification. The current study aims to explore the potential predictive value of serum Gal-3 for severe abdominal aortic calcification (AAC) and AAC progression in MHD patients.
A prospective cohort who underwent hemodialysis during July 2014 at the Blood Purification Center of Ruijin Hospital were followed up for 3 years. Two AAC assessments were performed: one at baseline and one after the 3-year follow-up period. Serum Gal-3 was detected with quantitative ELISA kits. SPSS 23.0 and MedCalc 11.4.2.0 were used to analyze the data.
One hundred and fifty-two patients were recruited. Approximately 59.9% were male, the median age was 60 (50-67) years. Logistic regression analysis indicated that serum Gal-3 was an independent risk factor for both follow-up severe AAC and AAC progression. Receiver operating characteristic (ROC) curve analysis revealed significant prognostic value of serum Gal-3 for predicting severe AAC and AAC progression within 3 years.
We found serum Gal-3 is correlated to vascular calcification in ESRD patients. Gal-3 may be a potential biomarker of vascular calcification for MHD patients.
异位血管钙化是维持性血液透析（MHD）患者的常见并发症。据报道，半乳糖凝集素3（Gal-3）与心血管钙化有关。本研究旨在探讨血清Gal-3对MHD患者严重腹主动脉钙化（AAC）及AAC进展的潜在预测价值。
对2014年7月在瑞金医院血液净化中心接受血液透析的前瞻性队列进行了3年随访。进行了两次AAC评估：一次在基线时，一次在3年随访期后。使用定量ELISA试剂盒检测血清Gal-3。采用SPSS 23.0和MedCalc 11.4.2.0分析数据。
共纳入152例患者。约59.9%为男性，中位年龄为60（50-67）岁。逻辑回归分析表明，血清Gal-3是随访期严重AAC和AAC进展的独立危险因素。受试者工作特征（ROC）曲线分析显示，血清Gal-3对预测3年内严重AAC和AAC进展具有显著的预后价值。
我们发现血清Gal-3与终末期肾病（ESRD）患者的血管钙化相关。Gal-3可能是MHD患者血管钙化的潜在生物标志物。
